HR 3536
115th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Health programs administration and funding
Health technology, devices, supplies
Inflation and prices
Intellectual property
Medical research
Research and development
To require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.
Introduced: July 28, 2017
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 4, 2017
Referred to the Subcommittee on Health.
Jul 28, 2017
Referred to the House Committee on Energy and Commerce.
Jul 28, 2017
Introduced in House
Plain-English summary
This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2